Date | Title | Description | |
---|---|---|---|
03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
22 Jun 2021 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. | Download |
22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
02 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 January and 1 February 2024 | Download |
26 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 January and 25 January 2024 | Download |
19 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 12 January and 18 January 2024 | Download |
12 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 5 January and 11 January 2024 | Download |
05 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 29 December 2023 and 4 January 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
04 Apr 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2019 | Download |
19 Mar 2019 | R&D: new licenses, patents and registered trademarks | ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia | Download |
26 Feb 2019 | Informe Anual de Remuneraciones de los Consejeros | ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors | Download |
26 Feb 2019 | Informe Anual de Gobierno Corporativo | ROVI releases the 2018 Annual Corporate Governance Report | Download |
26 Feb 2019 | Otros sobre gobierno corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |